Published in Oncotarget on August 14, 2017
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist (2010) 4.68
Global challenges in liver disease. Hepatology (2006) 4.55
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol (2005) 4.37
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med (2011) 4.34
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol (2008) 3.34
Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab (2009) 3.16
Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol (2013) 3.12
The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch (2003) 2.58
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol (2002) 2.29
Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med (2001) 2.12
The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol (2002) 2.03
The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med (2013) 1.97
Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res (2001) 1.95
Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol (2000) 1.92
Glucose transporters: expression, regulation and cancer. Biol Res (2002) 1.74
HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol (2009) 1.73
Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol (2014) 1.69
Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol (2015) 1.68
GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am J Physiol Endocrinol Metab (2009) 1.55
Expression of glucose transporters in cancers. Biochim Biophys Acta (2012) 1.51
GLUT2 is a high affinity glucosamine transporter. FEBS Lett (2002) 1.47
Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med (2014) 1.43
Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol (2011) 1.21
Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med (2010) 1.18
GLUT2, glucose sensing and glucose homeostasis. Diabetologia (2014) 1.17
GLUT2 in pancreatic and extra-pancreatic gluco-detection (review). Mol Membr Biol (2002) 1.16
18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant (2009) 1.12
GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med (2004) 1.09
Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res (1998) 1.08
Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging (2003) 1.03
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver Int (2011) 1.03
Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer (2010) 1.01
Biomarkers for hepatocellular carcinoma. Int J Hepatol (2012) 1.00
Hepatic expression and cellular distribution of the glucose transporter family. World J Gastroenterol (2012) 0.98
FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. Cancer Lett (2011) 0.98
Management of hepatocellular carcinoma. Oncology (Williston Park) (2000) 0.97
Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med (2000) 0.92
The actual five-year survival rate of hepatocellular carcinoma patients after curative resection. Yonsei Med J (2006) 0.85
Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun (2009) 0.84
Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology (2017) 0.83
P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol (2009) 0.83
Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. Oncotarget (2015) 0.82
Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis. Cancer Res (1993) 0.81
Different functional domains of GLUT2 glucose transporter are required for glucose affinity and substrate specificity. Endocrinology (1998) 0.81
Staging for hepatocellular carcinoma: complex and confusing. Gastroenterology (2014) 0.80
Both GLUT-1 and GLUT-14 are Independent Prognostic Factors in Gastric Adenocarcinoma. Ann Surg Oncol (2015) 0.79
Prognostic value of SUVmean in oropharyngeal and hypopharyngeal cancers: comparison with SUVmax and other volumetric parameters of 18F-FDG PET. Clin Nucl Med (2015) 0.78
Could GLUT12 be a Potential Therapeutic Target in Cancer Treatment? A Preliminary Report. J Cancer (2015) 0.77
The glucose transporter-2 (GLUT2) is a low affinity dehydroascorbic acid transporter. Biochem Biophys Res Commun (2011) 0.77